Short answer
BIOLIFE SOLUTIONS INC (BLFS) filed an 8-K current report with the SEC on July 22, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Employee town-hall presentation related to the announced merger, furnished as Exhibit 99.2.
BIOLIFE SOLUTIONS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Employee town-hall presentation related to the announced merger, furnished as Exhibit 99.2
- Presentation may provide employees and investors additional transaction context beyond the merger announcement
Item 2.02 · Results of Operations and Financial Condition
- Preliminary unaudited revenue announcement for Q2 2026 ended June 30, 2026
- Full financial details contained in Exhibit 99.1, requiring review for revenue figures and operating trends
Item 7.01 · Regulation FD Disclosure
- BioLife and Repligen entered a merger agreement, creating a material strategic transaction for BioLife shareholders
- Joint press release contains transaction terms and expected shareholder implications
Item EX-99.1 · Exhibit EX-99.1
- Repligen to acquire BioLife for approximately $1.5B enterprise value, offering $31.00 per share and a 24% premium to 90-day VWAP
- Consideration mix: 64% Repligen stock and 36% cash, including $11.25 cash plus 0.1442 Repligen shares per BioLife share
- BioLife shareholders gain immediate cash and continued upside exposure, while accepting transaction-completion and stock-value risks
- BioLife preliminary Q2 revenue $28.5M, up 21% from $23.4M; standalone earnings call canceled pending acquisition
- Closing targeted for Q4 2026, subject to regulatory clearance, BioLife shareholder approval, and customary conditions
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other BIOLIFE SOLUTIONS INC 8-K filings
Get the next BLFS 8-K as it lands
Follow BLFS for push alerts, or ask the research agent what this filing means.